<SEC-DOCUMENT>0001346824-25-000047.txt : 20251110
<SEC-HEADER>0001346824-25-000047.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110164010
ACCESSION NUMBER:		0001346824-25-000047
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88806
		FILM NUMBER:		251466947

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RA CAPITAL MANAGEMENT, L.P.
		CENTRAL INDEX KEY:			0001346824
		ORGANIZATION NAME:           	
		EIN:				830406777
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY STREET, 18TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-778-2500

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY STREET, 18TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RA CAPITAL MANAGEMENT, LLC
		DATE OF NAME CHANGE:	20051213
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
		<previousAccessionNumber>0001104659-24-082640</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001346824</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>4</amendmentNo>
	      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <dateOfEvent>11/06/2025</dateOfEvent>
	  <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001610618</issuerCIK>
        <issuerCUSIP>171757206</issuerCUSIP>
		<issuerName>CIDARA THERAPEUTICS, INC.</issuerName>

        <address>
          <com:street1>6310 NANCY RIDGE DRIVE</com:street1>
          <com:street2>SUITE 101</com:street2>          <com:city>SAN DIEGO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </address>
      </issuerInfo>

	  	  <authorizedPersons>

		<notificationInfo>
			<personName>Peter Kolchinsky</personName>
			<personPhoneNum>617.778.2500</personPhoneNum>
				<personAddress>
					<com:street1>RA Capital Management, L.P.</com:street1>
					<com:street2>200 Berkeley Street, 18th Floor</com:street2>					<com:city>Boston</com:city>
					<com:stateOrCountry>MA</com:stateOrCountry>
					<com:zipCode>02116</com:zipCode>
				</personAddress>
		</notificationInfo>
			</authorizedPersons>
	    </coverPageHeader>

	<reportingPersons>


			<reportingPersonInfo>
									<reportingPersonCIK>0001346824</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>RA Capital Management, L.P.</reportingPersonName>





				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3372923.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3372923.00</sharedDispositivePower>
												<aggregateAmountOwned>3372923.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>10.7</percentOfClass>





			  			  <typeOfReportingPerson>IA</typeOfReportingPerson>

			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001384859</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Peter Kolchinsky </reportingPersonName>





				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3372923.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3372923.00</sharedDispositivePower>
												<aggregateAmountOwned>3372923.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>10.7</percentOfClass>








			  			  <typeOfReportingPerson>HC</typeOfReportingPerson>



			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001619841</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Rajeev Shah</reportingPersonName>





				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3372923.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3372923.00</sharedDispositivePower>
												<aggregateAmountOwned>3372923.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>10.7</percentOfClass>








			  			  <typeOfReportingPerson>HC</typeOfReportingPerson>



			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001315082</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>RA Capital Healthcare Fund, L.P.</reportingPersonName>






				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3365523.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3365523.00</sharedDispositivePower>
												<aggregateAmountOwned>3365523.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>10.7</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>
			</reportingPersons>


	<items1To7>
		<item1>
			<securityTitle>Common Stock, $0.0001 par value per share</securityTitle>
			<issuerName>CIDARA THERAPEUTICS, INC.</issuerName>

			<issuerPrincipalAddress>
			 <com:street1>6310 NANCY RIDGE DRIVE</com:street1>
			  <com:street2>SUITE 101</com:street2>			  <com:city>SAN DIEGO</com:city>
			  <com:stateOrCountry>CA</com:stateOrCountry>
			  <com:zipCode>92121</com:zipCode>
			</issuerPrincipalAddress>

						<commentText>Item 1 of the Statement is amended and supplemented as follows:

This Amendment No. 4 (this "Amendment No. 4" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on July 25, 2024, and amended on November 26, 2024, June 30, 2025 and August 11, 2025 (as amended, the "Statement") by the Reporting Persons. This Amendment No. 4 is being filed to report the dilution of the Reporting Persons' beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 4 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.</commentText>
					</item1>

				<item2>
			<filingPersonName>This Schedule 13D/A is being filed on behalf of RA Capital Management, L.P. ("RA Capital"), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Fund"). RA Capital, Dr. Kolchinsky, Mr. Shah and the Fund are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this Schedule 13D/A jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, (the "Act"), is attached hereto as Exhibit 99.1.

The Fund directly holds: (i) 3,365,523 shares of common stock; (ii) Series A preferred stock ("Preferred Stock") convertible for up to 6,296,920 shares of common stock; (iii) pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 1,286,786 shares of common stock; and (iv) 7,400 stock options (right to buy) scheduled to vest within 60 days of this filing held by Dr. Resnick for the benefit of RA Capital. Each of the Preferred Stock and the Pre-Funded Warrants contains a provision (the "Beneficial Ownership Blockers") which precludes conversion of the Preferred Stock or exercise of the Pre-Funded Warrants to the extent that, following conversion or exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. The Fund is currently prohibited from converting the Preferred Stock and exercising the Pre-Funded Warrants by virtue of the Beneficial Ownership Blockers.

RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for each of the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in its portfolio, including the shares of the Issuer's common stock reported herein. Because the Fund has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13D/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13D/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

</filingPersonName>			<principalBusinessAddress>The address of the principal business office of each of the Reporting Persons is 200 Berkeley Street, 18th Floor, Boston, MA 02116.</principalBusinessAddress>			<principalJob>The Fund is a private investment vehicle. RA Capital provides investment management services to the Fund. The principal occupation of each of Dr. Kolchinsky and Mr. Shah is investment management.</principalJob>			<hasBeenConvicted>During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>			<convictionDescription>During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</convictionDescription>			<citizenship>See Item 6 of the cover pages.</citizenship>		</item2>



				<item5>
			 <percentageOfClassSecurities>Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon upon 31,439,371 shares of common stock outstanding as of November 3, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025, and giving effect to stock options, to the extent exercisable within 60 days hereof, as referenced herein.
</percentageOfClassSecurities>			<numberOfShares>Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.</numberOfShares>			<transactionDesc>Except as set forth below, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.

													No.		Price Per
Transaction					Purchaser	Date 		Shares	Share ($)

Vest Stock Option (Right to Buy)	RA Capital 	01/03/2026	7,400	(1) (2)

(1) This option represents a right to purchase a total of 22,200 shares of the Issuer's common stock. 1/3rd of the total number of shares shall vest on January  3, 2026 and the remaining 2/3rds of the shares shall vest in equal monthly installments over a two year period. The vesting of the option is subject to Dr. Resnick's continuous service to the Issuer through each vesting date. This option has an exercise price of $26.62 per share.

(2) Represents future vesting options within 60 days from the filing date of this Amendment No. 4.
</transactionDesc>			<listOfShareholders>No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities subject to this Statement. </listOfShareholders>			<date5PercentOwnership>Not Applicable.</date5PercentOwnership>		</item5>


				<item7>
			<filedExhibits>Exhibit 99.1	Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13D/A filed with the SEC on June 30, 2025).</filedExhibits>
		</item7>

	</items1To7>

<signatureInfo>

	<signaturePerson>
		<signatureReportingPerson>RA Capital Management, L.P.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Peter Kolchinsky</signature>
				<title>By Peter Kolchinsky, Authorized Signatory</title>
				<date>11/10/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Peter Kolchinsky </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Peter Kolchinsky</signature>
				<title>Peter Kolchinsky</title>
				<date>11/10/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Rajeev Shah</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Rajeev Shah</signature>
				<title>Rajeev Shah</title>
				<date>11/10/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>RA Capital Healthcare Fund, L.P.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Peter Kolchinsky</signature>
				<title>By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager</title>
				<date>11/10/2025</date>
			</signatureDetails>

	</signaturePerson>



</signatureInfo>
</formData>


</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
